Clinical trials recruiting in Stade, Germany

Phase breakdown

Conditions recruiting in Stade, Germany

Recruiting trials in Stade, Germany

• Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
  NCT07242352 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
  NCT05704829 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients
  NCT04405583 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Stade, Germany?

4 recruiting trials have at least one study site in Stade, Germany.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.